Oncology: CARG-2020
Prevention and treatment of tumors recurrence
CARG-2020 DNA Plasmid Designed to Target Multiple Pathways

First in class oncolytic artificial virus delivering three immuno-modulators – IL-12/IL-17RA/shRNA-PD-L1 – to create a broad spectrum of activities
Preclinical safety and efficacy demonstrated in multiple animal models using different routes of administration:
- Colorectal cancer (intra-tumoral and intravenous)
- Ovarian cancer (Intra-peritoneal)
- Hepatocellular carcinoma (intra-tumoral)
- Breast cancer, brain cancer and melanoma animal studies are ongoing (intra-tumoral)
Demonstrated robust efficacy in preclinical studies to date:
- Regression of large tumors
- Prevention of tumor recurrence in both CRC and ovarian cancer
- Abscopal effect (efficacy against distal, un-injected tumors)
- Activates broad immune responses through multiple mechanisms of actions
- Significant impact on survival
Multiple efficacy animal studies in breast and melanoma models are in progress.
Current focus on Intra-tumoral delivery:
- Pre-IND meeting with the FDA held on December 2021
- IND is planned to be filed with the FDA in Q2, 2024